It was the press announcement heard around the world: a potential Covid-19 vaccine from the University of Oxford and pharmaceutical company AstraZeneca had not only been “tolerated” by patients, but “generated robust immune responses against the Sars-CoV-2 virus in all evaluated participants”. The project will now proceed to all-important phase 3 trials in Brazil and South Africa to test if it actually stops infection.
For a global population that has seen its movement curtailed and its health threatened, it was a welcome dose of good news. It is also a large feather in the cap for AstraZeneca, whose boss, Pascal Soriot, will unveil financial results for the first half of 2020 on Thursday.